September
2004 | Vol. 5, No. 2
1 AMA PRA Category 1 Credit
Table of Contents
Clinical Experience With Maintenance Rituximab in Low-Grade and Aggressive Non-Hodgkin’s Lymphoma
John P. Leonard, MD
Clinical Activity of Rituximab in Marginal Zone Lymphomas
Emanuele Zucca, MD
Learning Objectives | Back to top
Upon completion of this learning material, physicians should be able to:
- Identify the treatment strategies and clinical outcomes of maintenance therapy with rituximab in B-cell non-Hodgkin’s lymphoma
- Describe the various clinical trials of rituximab therapy in marginal zone lymphoma
Activity Goals | Back to top
An estimated 54,370 new cases of non-Hodgkin’s lymphoma (NHL) will be diagnosed in the US in 2004. Rituximab, an anti-CD20 monoclonal antibody, has proven activity in various aggressive and indolent lymphomas. Additionally, maintenance with rituximab has been shown to increase the quality and durability of response in lymphoma patients; however, the optimal timing and scheduling of maintenance rituximab remains to be determined. Marginal zone lymphoma is a relatively common form of NHL; however, as yet there is no optimal treatment regimen for patients with marginal zone lymphoma, and possible treatment modalities such as surgery and radiation therapy pose risks of morbidity and mortality for patients. In recent trials, rituximab has demonstrated efficacy in marginal zone lymphoma, with few severe toxicities.
The purpose of this activity is to apprise physicians on recent clinical trials of rituximab treatment and retreatment in non-Hodgkin’s lymphoma.
Target Audience | Back to top
This publication is intended for medical oncologists involved in the care of patients with lymphoma. No specific skills or knowledge other than a basic training in oncology are required for successful participation in this activity.
Accreditation | Back to top
Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Release date: September 30, 2004
Expiration date: September 30, 2005
Disclosure Policy | Back to top
As a sponsor accredited by the Accreditation Council for Continuing Medical Education, Physicians’ Education Resource must ensure balance, independence, objectivity and scientific rigor in all its sponsored activities. All faculty participating in a sponsored activity are expected to disclose to the activity audience any significant financial interest or other relationship (1) with the manufacturer(s) of any commercial product(s) and (2) with any commercial supporters of the activity. (Significant financial interest or other relationships can include such things as grants or research support, employee, consultant, major stockholder, member of speaker’s bureau, etc.) The intent of this disclosure is not to prevent an author with a significant financial or other relationship from publishing an article, but rather to provide readers with information on which they can make their own judgements. It remains for the readers to determine whether the author’s interests or relationships may influence the publication with regard to exposition or conclusion.
John P. Leonard, MD
Grant or Research Support – Amgen, Biogen Idec, Chiron, Coley Pharmaceutical, Corixa, GlaxoSmithKline, Immunomedics, Millennium, Protein Design Labs, Seattle Genetics;
Paid Consultant – Amgen, Chiron, Corixa, Cougar Biotechnology, Genentech/Biogen Idec, GlaxoSmithKline, Immunomedics, Millennium;
Speaker’s Bureau – Corixa, Genentech/Biogen Idec, GlaxoSmithKline
Emanuele Zucca, MD
Grant or Research Support – Roche Pharmaceuticals
The articles in this CME activity might include discussion of investigational and/or unlabeled uses of drugs. If an article includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this newsletter for FDA-approved dosing, indications, and warnings.
Monographs in Lymphoma (ISSN: 1528-5537) is produced by Physicians’ Education Resource, Dallas, TX. An unrestricted educational grant for this publication was provided by Genentech BioOncology/Biogen Idec.
Cover Illustration | Back to top
MALT lymphoma is a relatively common marginal zone lymphoma comprising approximately 8% of all non-Hodgkin’s lymphoma (NHL) cases. Nonrandom translocations have been reported in MALT, the most common of which are t(11;18)(q21;q21) and t(14;18)(q32;q21). The t(11;18)(q21;q21) is a reciprocal translocation that results in the fusion of API2 on chromosome 11 to MALT1 on chromosome 18. This translocation can be detected by fluorescence in situ hybridization (upper left panel). Arrows over the diagrams on the right represent the most frequent (> 30%) breakpoints in API2 and MALT1. The Api2-Malt1 fusion protein is expressed in MALT lymphomas and might play a role in MALT lymphoma cell proliferation and survival based on the functions of Api2 and Malt1. Api2 is an antiapoptotic protein that inhibits caspases 3, 7, and 9 whereas Malt1 activates NFκB. The presence of t(11;18)(q21;q21) is correlated with resistance of MALT to antibiotic therapy versus Helicobacter pylori. Please see Dr. Zucca’s article for more information. Abbreviations: CARD = caspase recruitment domain; D = death domain; IAP = inhibitor of apoptosis domain; IgG = Immunoglobulin G-like domain; RING = zinc-binding RING finger domain (Illustrator: Erin Moore)
The views and opinions expressed in this publication are those of the authors and do not necessarily reflect the views of the sponsor or publisher. Although great care has been taken in compiling and checking the information given in this publication to ensure accuracy, the authors, Genentech BioOncology/ Biogen Idec, and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this publication, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.
Please consult full prescribing information for any drugs or procedures discussed within.
All rights reserved. No part of this publication may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.
©Copyright 2004 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.
All correspondence should be directed to:
Editor, Monographs in Lymphoma
Physicians’ Education Resource
3535 Worth St.
Suite 4802
Dallas, TX 75246
Phone: (214) 820-8079
Fax: (214) 820-8844
E-mail: editor@perlp.com
Editorial Staff:
Publishing Manager – B. Diane Gambill, PhD
Assistant Publishing Manager – David Lee, PhD
Managing Editor – Jennifer Klem, PhD
Manager, CME and Content – Preeta Tyagi, PhD
Senior Medical Editor – Jay Delmar, PhD
Associate Medical Editor – Jill Cowherd
Medical Editor/Proofreader – Pete Sloan
Acquisitions – Anissa Mitchell
Design & Production:
Art Director – Todd J. Hagler
Senior Graphic Artist – Kelly D. Martin
Graphic Artist – Kevin Graves
ISSN: 1528-5537
Back to top
|
